Abstract
Antiplatelet therapy is integral to the acute and long-term management of acute coronary syndromes (ACSs) and for minimizing the thrombotic complications of percutaneous coronary intervention (PCI). This article reviews the most commonly used antiplatelet agents in ACS therapy--aspirin, adenosine diphosphate (ADP)-receptor blockers, and glycoprotein IIb/IIIa inhibitors. More recent data are also reviewed on novel ADP-receptor blockers and thrombin inhibitors before addressing issues of adherence to antiplatelet regimens.
MeSH terms
-
Acute Coronary Syndrome / drug therapy*
-
Acute Coronary Syndrome / therapy
-
Angioplasty / adverse effects
-
Aspirin / administration & dosage
-
Aspirin / adverse effects
-
Aspirin / therapeutic use
-
Drug Interactions
-
Humans
-
Medication Adherence
-
Platelet Aggregation Inhibitors / administration & dosage
-
Platelet Aggregation Inhibitors / adverse effects
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Platelet Glycoprotein GPIIb-IIIa Complex / administration & dosage
-
Platelet Glycoprotein GPIIb-IIIa Complex / adverse effects
-
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
-
Purinergic P2Y Receptor Antagonists / administration & dosage
-
Purinergic P2Y Receptor Antagonists / adverse effects
-
Purinergic P2Y Receptor Antagonists / therapeutic use
-
Thrombosis / etiology
-
Thrombosis / prevention & control
Substances
-
Platelet Aggregation Inhibitors
-
Platelet Glycoprotein GPIIb-IIIa Complex
-
Purinergic P2Y Receptor Antagonists
-
Aspirin